HRP20151443T1 - Terapijsko sredstvo protiv stenoze kralježniäśnog kanala - Google Patents

Terapijsko sredstvo protiv stenoze kralježniäśnog kanala Download PDF

Info

Publication number
HRP20151443T1
HRP20151443T1 HRP20151443TT HRP20151443T HRP20151443T1 HR P20151443 T1 HRP20151443 T1 HR P20151443T1 HR P20151443T T HRP20151443T T HR P20151443TT HR P20151443 T HRP20151443 T HR P20151443T HR P20151443 T1 HRP20151443 T1 HR P20151443T1
Authority
HR
Croatia
Prior art keywords
spinal canal
stenosis
royal
channel
canal stenosis
Prior art date
Application number
HRP20151443TT
Other languages
English (en)
Croatian (hr)
Inventor
Keiichi Kuwano
Original Assignee
Nippon Shinyaku Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co., Ltd. filed Critical Nippon Shinyaku Co., Ltd.
Publication of HRP20151443T1 publication Critical patent/HRP20151443T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
HRP20151443TT 2008-06-23 2009-06-22 Terapijsko sredstvo protiv stenoze kralježniäśnog kanala HRP20151443T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008162638 2008-06-23
EP09770106.4A EP2292231B1 (fr) 2008-06-23 2009-06-22 Agent thérapeutique pour la sténose du canal spinal
PCT/JP2009/061285 WO2009157396A1 (fr) 2008-06-23 2009-06-22 Agent thérapeutique pour la sténose du canal spinal

Publications (1)

Publication Number Publication Date
HRP20151443T1 true HRP20151443T1 (hr) 2016-01-29

Family

ID=41444462

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20151443TT HRP20151443T1 (hr) 2008-06-23 2009-06-22 Terapijsko sredstvo protiv stenoze kralježniäśnog kanala

Country Status (15)

Country Link
US (1) US8629145B2 (fr)
EP (1) EP2292231B1 (fr)
JP (1) JP5527205B2 (fr)
KR (1) KR101626168B1 (fr)
CN (3) CN102065863A (fr)
CA (1) CA2728089C (fr)
CY (1) CY1117080T1 (fr)
DK (1) DK2292231T3 (fr)
ES (1) ES2557303T3 (fr)
HR (1) HRP20151443T1 (fr)
HU (1) HUE025885T2 (fr)
PL (1) PL2292231T3 (fr)
PT (1) PT2292231E (fr)
SI (1) SI2292231T1 (fr)
WO (1) WO2009157396A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20201352T1 (hr) * 2008-02-28 2020-11-27 Nippon Shinyaku Co., Ltd. Inhibitor fibroze
KR20170024165A (ko) 2009-06-26 2017-03-06 니뽄 신야쿠 가부시키가이샤 결정
WO2011024874A1 (fr) * 2009-08-26 2011-03-03 日本新薬株式会社 Sels d'addition avec une base
EP4331607B1 (fr) * 2015-12-02 2025-04-30 Nippon Shinyaku Co., Ltd. Composition pharmaceutique solide contenant du 2-{4-[n-(5,6-diphénylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n-(méthylsulfonyl)acétamide
WO2018019296A1 (fr) * 2016-07-29 2018-02-01 成都苑东生物制药股份有限公司 Composé d'aminopyrazine, sel ou isomère, son procédé de préparation et son application
JOP20190204A1 (ar) 2017-03-08 2019-09-05 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على سيليكسيباغ
BR112020005428A2 (pt) 2017-09-28 2020-09-29 Nippon Shinyaku Co., Ltd. cristal de forma-i, cristal de forma-ii, composição farmacêutica, receptor agonístico pgi2, agente terapêutico compreendendo os referidos cristais e uso dos mesmos
US10407396B2 (en) * 2017-11-16 2019-09-10 Apotex Inc. Crystalline form of selexipag
US11382912B2 (en) 2017-11-16 2022-07-12 Nippon Shinyaku Co., Ltd. Controlled-release preparation
WO2020157730A1 (fr) 2019-02-03 2020-08-06 Patel Jayendrakumar Dasharathlal Composition pharmaceutique à libération contrôlée de sélexipag ou son métabolite actif
UY38848A (es) * 2019-08-19 2021-02-26 Nippon Shinyaku Co Ltd Sal
CN114555088A (zh) 2019-10-23 2022-05-27 埃科特莱茵药品有限公司 包含赛乐西帕的药物组合物
US20230113077A1 (en) 2020-01-31 2023-04-13 Actelion Pharmaceuticals Ltd Controlled release selexipag composition
TW202241425A (zh) 2021-01-29 2022-11-01 瑞士商艾克泰聯製藥有限公司 用於製造二苯基吡𠯤衍生物之程序
TW202239408A (zh) 2021-01-29 2022-10-16 瑞士商艾克泰聯製藥有限公司 包含二苯基吡𠯤衍生物的醫藥組成物
JP7010404B1 (ja) 2021-03-31 2022-02-10 日本新薬株式会社 歩行障害治療剤
CA3215414A1 (fr) * 2021-03-31 2022-10-06 Nippon Shinyaku Co., Ltd. Agent therapeutique contre un trouble de la marche
WO2023131608A1 (fr) 2022-01-04 2023-07-13 Actelion Pharmaceuticals Ltd Compositions à libération contrôlée
WO2023214059A1 (fr) 2022-05-06 2023-11-09 Actelion Pharmaceuticals Ltd Composés de diphénylpyrazine utilisés en tant que promédicaments
WO2024017964A1 (fr) 2022-07-20 2024-01-25 Actelion Pharmaceuticals Ltd Composition pharmaceutique injectable comprenant un dérivé de diphénylpyrazine
WO2024133620A1 (fr) 2022-12-22 2024-06-27 Actelion Pharmaceuticals Ltd Test de dissolution in vitro
WO2024194449A1 (fr) 2023-03-23 2024-09-26 Actelion Pharmaceuticals Ltd Composition pharmaceutique comprenant un dérivé de diphénylpyrazine
WO2025196095A1 (fr) 2024-03-20 2025-09-25 Actelion Pharmaceuticals Ltd Composition pharmaceutique injectable pour le traitement de l'hypertension pulmonaire

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI316055B (fr) 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
RU2292337C2 (ru) * 2002-02-19 2007-01-27 Оно Фармасьютикал Ко., Лтд. Конденсированные производные пиридазина и лекарственные препараты, содержащие данные соединения в качестве активного ингредиента
ES2584606T3 (es) 2002-10-10 2016-09-28 Ono Pharmaceutical Co., Ltd. Microesferas que comprenden ONO-1301
HRP20201352T1 (hr) * 2008-02-28 2020-11-27 Nippon Shinyaku Co., Ltd. Inhibitor fibroze

Also Published As

Publication number Publication date
CA2728089A1 (fr) 2009-12-30
ES2557303T3 (es) 2016-01-25
KR101626168B1 (ko) 2016-05-31
CN103690541A (zh) 2014-04-02
WO2009157396A1 (fr) 2009-12-30
KR20110033125A (ko) 2011-03-30
EP2292231A4 (fr) 2012-03-28
CA2728089C (fr) 2017-04-11
CN102065863A (zh) 2011-05-18
EP2292231A1 (fr) 2011-03-09
CN105168218A (zh) 2015-12-23
US8629145B2 (en) 2014-01-14
HUE025885T2 (en) 2016-05-30
CY1117080T1 (el) 2017-04-05
PL2292231T3 (pl) 2016-03-31
PT2292231E (pt) 2015-12-31
SI2292231T1 (sl) 2016-03-31
JP5527205B2 (ja) 2014-06-18
EP2292231B1 (fr) 2015-10-21
JPWO2009157396A1 (ja) 2011-12-15
DK2292231T3 (en) 2015-12-14
US20110105518A1 (en) 2011-05-05

Similar Documents

Publication Publication Date Title
HRP20151443T1 (hr) Terapijsko sredstvo protiv stenoze kralježniäśnog kanala
HRP20201243T1 (hr) N-piperidinil acetamidni derivati kao blokatori kalcijevog kanala
HRP20201352T1 (hr) Inhibitor fibroze
WO2008096775A1 (fr) Agent thérapeutique pour la douleur
WO2011146808A3 (fr) Formulation topique pour inhibiteur de jak
CA3094580C (fr) Formulations orales d'analogues de cytidine et leurs procedes d'utilisation
BRPI0811436A2 (pt) Composto, uso de um composto, composição farmacêutica, e, metódos para a terapia da dor em um animal de sangue quente, para a terapia da bexiga super ativa em um animal de sangue quente, e para preparar um composto.
WO2005091991A3 (fr) Procedes d'utilisation et compositions comprenant des composes destines au traitement et a la gestion de maladies ou de troubles de la peau
WO2014120808A8 (fr) Pyridone amides comme modulateurs des canaux sodiques
WO2007093450A3 (fr) Derives de catecholamine deuteries et medicaments comprenant de tels composes
BRPI1011031A2 (pt) sal de arginina de um agente ativo, composição líquida ou em gel farmaceuticamente aceitável, kit, método para tratamento de uma desordem neurológica e método para tratar ou amenizar a doença de parkinson em um paciente que necessite deste.
MX377802B (es) Metodos y composiciones para trastornos del sueño y otros trastornos.
DK2451445T3 (da) Fremgangsmåde til at tørre bibw2992, dets salte og faste farmaceutiske formuleringer omfattende denne aktive ingrediens
IL228904A0 (en) Use of milankiperan, or a suitable pharmaceutical salt, in the preparation of a drug for the treatment of fibromyalgia
NZ605469A (en) Nalbuphine-based formulations and uses thereof
HRP20100577T1 (hr) Uporaba agomelatina za dobivanje lijeka s ciljem liječenja općeg poremećaja anksioznosti
WO2008052139A3 (fr) Doxepine à dose ultrafaible, et ses procédés d'utilisation pour traiter des troubles du sommeil
IL198180A (en) Salt p- toluene 5-amino-3-sulfonic acid (2'-0-acetyl-3'-deoxy-ß-d-riboforanosyl) -3h-thiazole [5,4- d] pyrimidine-2-on crystalline form , A pharmaceutical product containing it, its use in the preparation of a drug and methods for its manufacture
WO2007136741A3 (fr) N-desméthyldoxépine et procédés pour traiter les troubles du sommeil l'utilisant
ZA201007391B (en) Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium in the blood
JP2015518007A5 (fr)
CA2736751A1 (fr) Sels de n-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridin-3-yl]-2-methyl-4'-(trifluoromethoxy)-[1,1'-biphenyl]-3-carboxamide
TW200716204A (en) Pharmaceutical composition
IL187575A (en) Benzofuranyl derivatives ,pharmaceutical formulations comprising the same and use thereof in the preparation of medicaments for the treatment of 5-ht6-receptor related disorders
WO2012024583A3 (fr) Composés oxystérol